Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001051438 | SCV001215592 | pathogenic | Mucopolysaccharidosis, MPS-IV-A | 2021-08-31 | criteria provided, single submitter | clinical testing | |
Laboratory of Diagnosis and Therapy of Lysosomal Disorders, |
RCV001051438 | SCV001547586 | pathogenic | Mucopolysaccharidosis, MPS-IV-A | 2021-02-01 | criteria provided, single submitter | curation | Splicing variant in canonical site (PVS1_very strong); in vivo functional studies supportive of a damaging effect on the gene product (low to null enzymatic activity in homozygotes; PS3_moderate); absent from gnomAD v2.1.1 (PM2_moderate) |
Genome- |
RCV001051438 | SCV002045042 | pathogenic | Mucopolysaccharidosis, MPS-IV-A | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Foundation for Research in Genetics and Endocrinology, |
RCV001051438 | SCV003845189 | pathogenic | Mucopolysaccharidosis, MPS-IV-A | 2023-03-21 | criteria provided, single submitter | clinical testing | A homozygous 3’splice site variation in intron 1 of the GALNS gene downstream of exon 1 was detected. The observed variant c.120+1G>C has not been reported in the 1000 genomes and ExAC databases. The variant has previously been reported in a patient affected with MPS IVA (Bidchol et al. 2014). The in-silico prediction of the variant is damaging by MutationTaster2. In summary, the variant meets our criteria to be classified as pathogenic. |